Currently Viewing:
Newsroom
Currently Reading
Case Study Identifies New Trigger for CAR-T Cell Expansion in DLBCL in JCAR017 Trial
August 25, 2017 – Surabhi Dangi-Garimella, PhD
Study Does Not Find Sufficient Evidence of Medicinal Cannabis Use for Chronic Pain
August 25, 2017 – Alison Rodriguez
Gender Differences in the Brain Explain Why Men Have Higher Rates of ADHD
August 24, 2017 – Alison Rodriguez
Study Finds HPV Vaccination Underutilized by Childhood Cancer Survivors
August 24, 2017 – Surabhi Dangi-Garimella, PhD
End-of-Life Palliative Care Lowered Utilization for Patients With Cancer
August 23, 2017 – Christina Mattina
What Is the Ideal Age for Screening Mammography?
August 23, 2017 – Surabhi Dangi-Garimella, PhD
Probiotics Do Not Have a Significant Impact on Preventing Eczema, Asthma in Infants
August 23, 2017 – Alison Rodriguez
Financial Concerns Influence Care-Seeking Behavior of Childhood Cancer Survivors
August 21, 2017 – Surabhi Dangi-Garimella, PhD
FDA Approves Besponsa for Relapsed/Refractory Acute Lymphoblastic Leukemia
August 21, 2017 – Alison Rodriguez

Case Study Identifies New Trigger for CAR-T Cell Expansion in DLBCL in JCAR017 Trial

Surabhi Dangi-Garimella, PhD
Chimeric antigen receptor (CAR)-T cells can re-expand in a lymphoma patient months after the initial infusion and can also be active against the patientís cancer, according to a new study.
Chimeric antigen receptor (CAR)-T cells can re-expand in a patient months after the initial infusion and can also be active against the patient’s cancer. These are the findings of a single case study that was recently published in the New England Journal of Medicine.

In their correspondence to the journal, researchers from the Massachusetts General Hospital reported on the case of a 68-year old woman with refractory diffuse large–B-cell lymphoma with a BCL2 rearrangement and overexpressing MYC and BCL6. She had undergone 5 lines of treatment, including intensive infusional chemotherapy consisting of dose-adjusted etoposide, doxorubicin, and cyclophosphamide with vincristine and prednisone plus rituximab. One of the treatments also included intermediate-intensity allogeneic stem-cell transplantation.

Her disease was refractory to all 5 lines of treatment, after which she was enrolled in a trial of JCAR017, a CD19-directed CAR-T treatment. The patient was free of graft-versus host disease (GVHD) and was not on immunosuppressive treatment when she was enrolled. A new brain lesion was diagnosed at the time of her enrollment.

Following lymphodepleting fludarabine–cyclophosphamide, the women was infused with JCAR017. She did not exhibit cytokine release syndrome, neurotoxicity, or GVHD following the infusion—typical adverse effects associated with CAR-T treatment.

A subsequent scan 1 month after the JCAR017 infusion showed complete remission of the brain lesion, but restaging after 2 months showed subcutaneous disease, which was resected with incisional therapy.

Pharmacokinetic testing showed significant expansion of CAR-T cells. The woman’s central nervous system response was durable and she remained in remission at 12 months after treatment, which means CAR-T cells can cross the blood-brain barrier.

The authors write that re-expansion of the CAR-T cells was in response to the biopsy procedure conducted in the patient, when the presence of tumor cells alone were not sufficient to stimulate a response.

Reference

Abramson JS, McGree B, Noyes S, et al. Anti-CD19 CAR T cells in CNS diffuse large-B-cell lymphoma. N Engl J Med. 2017;377:783-784. doi: 10.1056/NEJMc1704610. 

 
Copyright AJMC 2006-2020 Clinical Care Targeted Communications Group, LLC. All Rights Reserved.
x
Welcome the the new and improved AJMC.com, the premier managed market network. Tell us about yourself so that we can serve you better.
Sign Up